% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • greens150 greens150 Jun 5, 2013 8:07 AM Flag

    Excellent Guidance for '13 and Expectations for 2014

    Always under-promise and over-deliver. Their reps must have been hitting the pavement really good and have been seeing great responses from Doctors to give that type of guidance. If they say $150mm, I'm thinking $175-$2000mm.

    As for 2014, remember that prescriptions are like subscriptions, recurring revenue. $150mm for 6 doesn't mean $300mm for 12, it means more like $500mm to $750mm for 12 months as there will be patients that get prescriptions in Jun-Aug that continue into 2014, as well as many that start in Sept-Dec that take Belviq at a minimum into March and some throughout '14; plus all the NEW prescriptions that are written in '14 from a combination of Eisai's efforts as well as compounding word of mouth from the patients that have taken it in the 1st 6 months.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 150, I too agree. 150M is a very modest projection once you read SpencSA 10,000 scripts to start in June and going on from there; that's extremely modest! But why I suggest 0.5B in the first year is because 150M x 2 = 300M, doesn't account for exponential growth over that same period which after 12 months should be closer to $500M full year guidance. Even if we accept a flat line via Eisai, that's 300M/yr and this is news the Street is going to have to consume. I maintain 0.5B is a fair estimate based on Eisai's number calculating in exponential growth.=SV

    • I have to agree with you. I also believe that base upon ARNA and EISAI's history they are not out to pump a medication or their stock and are being conservative. I really like that. I hate companies that pump and dump without delivering, like DNDN and VVUS.

      GLTA Longs

      Sentiment: Hold

1.52+0.05(+3.40%)Feb 12 4:00 PMEST